Results 121 to 130 of about 58,767 (165)
Some of the next articles are maybe not open access.
Plasminogen Activator Inhibitor 1 and Plasminogen Activator Inhibitor 2 in Various Disease States
Thrombosis and Haemostasis, 1988SummaryThe association of increased PA-inhibitor (PAI) activity and of PAI-1 and PAI-2 antigen levels with different pathological conditions was studied in a collective of over 300 patients. PAI-1 and PAI-2 levels were measured by specific radioimmunoassays.
E K, Kruithof, A, Gudinchet, F, Bachmann
openaire +2 more sources
Plasminogen Activator Inhibitor-1
2008Fibrinolysis, the dissolution of fibrin clots, is an integral component of the hemostatic system that involves the concerted action of a complex system of zymogens, activators, and inhibitors [1]. Plasmin, the primary protease of the fibrinolysic system, digests fibrin, thereby converting insoluble clot to soluble fibrin degradation products.
Daniel T. Eitzman +2 more
openaire +1 more source
Development of Inhibitors of Plasminogen Activator Inhibitor-1
2011Plasminogen activator inhibitor-1 (PAI-1) belongs to the serine protease inhibitor super family (serpin) and is the primary inhibitor of both the tissue-type (tPA) and urokinase-type (uPA) plasminogen activators. PAI-1 has been implicated in a wide range of pathological processes where it may play a direct role in a variety of diseases.
Shih-Hon, Li, Daniel A, Lawrence
openaire +2 more sources
Plasminogen Activators and Plasminogen Activator Inhibitor 1 in Urinary Tract Cancer
Urologia Internationalis, 1994The plasminogen activation system is considered to play an important role in cancer growth and metastasis. Both plasminogen activators (PAs) and their fast-acting inhibitors are produced in tumor cells and their surrounding tissues. In order to clarify the influence of the existence of malignant tumor in urinary tract on the systemic fibrinolytic ...
H, Bashar +8 more
openaire +2 more sources
Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Stroke Patients
Stroke, 1996Background and Purpose Abnormal endogenous fibrinolytic activity may be a risk factor for stroke. Since the possible variation of tissue-type plasminogen activator (TPA) antigen and plasminogen activator inhibitor-1 (PAI-1) antigen concentrations over time after stroke has been rarely studied, it was examined in plasma from ...
A, Lindgren +4 more
openaire +2 more sources
Plasminogen activator inhibitor-1 modulates adipocyte differentiation
American Journal of Physiology-Endocrinology and Metabolism, 2006Increased plasminogen activator inhibitor-1 (PAI-1) is linked to obesity and insulin resistance. However, the functional role of PAI-1 in adipocytes is unknown. This study was designed to investigate effects and underlying mechanisms of PAI-1 on glucose uptake in adipocytes and on adipocyte differentiation. Using primary cultured adipocytes from PAI-1+/
Xiubin, Liang +9 more
openaire +2 more sources
Plasminogen activator inhibitor‐1 and diabetic nephropathy
Nephrology, 2005SUMMARY: Diabetic nephropathy is characterized by excessive accumulation of extracellular matrix (ECM) in the kidney. Decreased ECM degradation as well as increased ECM synthesis plays an important role in ECM remodeling that favours tissue fibrosis. Plasminogen activator (PA)/plasmin/PA inhibitor (PAI) system is involved in ECM degradation and PAI‐1 ...
Hi Bahl, Lee, Hunjoo, Ha
openaire +2 more sources
Plasminogen Activator Inhibitor-1 in Vascular Thrombosis
Current Drug Targets, 2007Thrombotic complications of vascular disease constitute the leading cause of morbidity and mortality in much of the developed world. Current drug therapies available to treat the thrombotic component of arterial and venous vascular complications remain limited.
Randal J, Westrick, Daniel T, Eitzman
openaire +2 more sources
Stability of Plasminogen Activator Inhibitor 1 (PAI-1)
Thrombosis and Haemostasis, 1989SummaryThe stability of PAI-activity has been studied at different conditions. The inactivation followed first order kinetics. Lowering the temperature and decreasing the pH both, increased the stability of PAI-1 dramatically. Addition of the PAI-1 binding protein, vitronectin, to reactivated PAI-1, about doubled the halflife of PAI-1 at all conditions
T L, Lindahl +2 more
openaire +2 more sources
Genetic Architecture of Tissue-Type Plasminogen Activator and Plasminogen Activator Inhibitor-1
Seminars in Thrombosis and Hemostasis, 2008Important biochemical constituents of the fibrinolytic system include tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1). In the current review, we aim to describe the genetic architecture of t-PA and PAI-1. Several genetic polymorphisms in the T-PA and PAI-1 gene have been found to be associated with t-PA and PAI-1 ...
Asselbergs, Folkert W. +5 more
openaire +3 more sources